Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for reversal of rocuronium-induced neuromuscular block in pediatric ENT surgery
ACTRN12613000131752Phase 2Completed
- Sponsor
- Ankara Training and Research Hospital
- Start
- Oct 2011
- Modality
- Classical Binding Small Molecules → Small Molecules, Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of Sugammadex, neostigmine, rocuronium and atropine in Adenotonsillitis and otitis media (2 arms), sponsored by Ankara Training and Research Hospital. Primary endpoint: Time to TOF ratio 0.9. Started Oct 2011; status: completed.
02
Drugs
Sugammadexneostigminerocuroniumatropine
03
Conditions
Adenotonsillitisotitis media
Beyond the preview
Go deeper on ACTRN12613000131752.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12613000131752.